Brady J F, Wang M H, Hong J Y, Xiao F, Li Y, Yoo J S, Ning S M, Lee M J, Fukuto J M, Gapac J M
Department of Chemical Biology and Pharmacognosy, College of Pharmacy, Rutgers University, Piscataway, New Jersey 08855-0789.
Toxicol Appl Pharmacol. 1991 Apr;108(2):342-54. doi: 10.1016/0041-008x(91)90123-v.
Diallyl sulfide (DAS) and other organosulfur compounds inhibit chemically induced carcinogenic and toxic responses in rodent model systems. A possible mechanism of action is the inhibition of the hepatic cytochrome P450IIE1-dependent bioactivation of the procarcinogens and protoxicants. Previous work showed competitive inhibition by DAS of N-nitrosodimethylamine (NDMA) demethylase activity in vitro, and a reduction in the microsomal level of P450IIE1 after in vivo treatment with DAS. The present studies demonstrated a time- and dose-dependent decrease of hepatic microsomal P450IIE1 activity, induction of P450IIB1 and pentoxyresorufin dealkylase activity, and moderate induction of ethoxyresorufin dealkylase activity by oral DAS treatment. DAS treatment elevated P450IIB1 mRNA but had no effect on P450IIE1 mRNA. Treatment with putative metabolites of DAS, diallyl sulfoxide and diallyl sulfone, led to similar modulations in monooxygenase activities, but the decrease of P450IIE1 activity by the sulfone occurred more rapidly. In studies in vitro, diallyl sulfone caused a metabolism-dependent inactivation of P450IIE1, but such inactivation was not observed with DAS or diallyl sulfoxide. The profile of microsomal testosterone metabolism after DAS treatment indicated an enhancement of P450IIB1-dependent 16 beta-hydroxylase activity, and a decrease in 6 beta-hydroxytestosterone production possibly related to a lower level of P450IIIA1 or IIIA2. When rats were subjected to a 48-hr fast and DAS treatment, the starvation-induced microsomal P450IIE1 level was decreased by DAS. Inhibition of hepatotoxicity due to exposure to P450IIE1 substrates, CCl4 and NDMA, by DAS was observed under a variety of treatment schedules.
二烯丙基硫醚(DAS)和其他有机硫化合物可抑制啮齿动物模型系统中化学诱导的致癌和毒性反应。一种可能的作用机制是抑制肝脏细胞色素P450IIE1依赖性的前致癌物和原毒物的生物活化。先前的研究表明,DAS在体外对N-亚硝基二甲胺(NDMA)脱甲基酶活性具有竞争性抑制作用,并且在体内用DAS处理后,微粒体中P450IIE1水平降低。目前的研究表明,口服DAS处理可使肝脏微粒体P450IIE1活性呈时间和剂量依赖性降低,诱导P450IIB1和戊氧基试卤灵脱烷基酶活性,并适度诱导乙氧基试卤灵脱烷基酶活性。DAS处理可提高P450IIB1 mRNA水平,但对P450IIE1 mRNA无影响。用DAS的假定代谢产物二烯丙基亚砜和二烯丙基砜处理,导致单加氧酶活性出现类似的调节,但砜使P450IIE1活性降低的速度更快。在体外研究中,二烯丙基砜导致P450IIE1发生代谢依赖性失活,但DAS或二烯丙基亚砜未观察到这种失活。DAS处理后微粒体睾酮代谢情况表明,P450IIB1依赖性16β-羟化酶活性增强,6β-羟基睾酮生成减少,这可能与P450IIIA1或IIIA2水平较低有关。当大鼠禁食48小时并接受DAS处理时,饥饿诱导的微粒体P450IIE1水平会因DAS而降低。在各种处理方案下,均观察到DAS对因接触P450IIE1底物四氯化碳和NDMA而产生的肝毒性具有抑制作用。